Aliases & Classifications for Endogenous Depression

MalaCards integrated aliases for Endogenous Depression:

Name: Endogenous Depression 12 15 74
Unipolar Depression 12 15 74
Clinical Depression 12 56 74
Depressive Disorder 45 74

Classifications:



External Ids:

Disease Ontology 12 DOID:1595
MeSH 45 D003866

Summaries for Endogenous Depression

Disease Ontology : 12 A mental depression that is characterized by a dysregulation of the endogenous opioid system and not of the monaminergic system.

MalaCards based summary : Endogenous Depression, also known as unipolar depression, is related to atypical depressive disorder and postpartum depression, and has symptoms including depressed - symptom An important gene associated with Endogenous Depression is MAOA (Monoamine Oxidase A), and among its related pathways/superpathways are Signaling by GPCR and Peptide ligand-binding receptors. The drugs Citalopram and Dopamine have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and heart, and related phenotypes are behavior/neurological and homeostasis/metabolism

Wikipedia : 77 Endogenous depression (melancholia) is an atypical sub-class of the mood disorder, major depressive... more...

Related Diseases for Endogenous Depression

Diseases related to Endogenous Depression via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 360)
# Related Disease Score Top Affiliating Genes
1 atypical depressive disorder 33.6 CRH HTR2A MAOA SLC6A4
2 postpartum depression 31.9 BDNF CRH MAOA SLC6A4
3 bipolar disorder 30.8 BDNF HTR1A HTR2A SLC6A4 TPH1
4 schizoaffective disorder 30.7 BDNF HTR2A SLC6A4
5 alcohol abuse 30.2 BDNF HTR2A SLC6A4
6 social phobia 30.1 HTR1A MAOA SLC6A4
7 conduct disorder 30.0 MAOA SLC6A4 TPH1
8 bipolar i disorder 30.0 BDNF HTR1A HTR2A SLC6A4
9 tobacco addiction 30.0 HTR2A MAOA SLC6A4 TPH1
10 temporal lobe epilepsy 29.9 BDNF HTR1A NPY
11 paranoid schizophrenia 29.9 BDNF HTR2A MAOA SLC6A4
12 craniopharyngioma 29.8 GNRH1 INS TRH
13 dysthymic disorder 29.8 GATA3 HTR2A MAOA SLC6A4
14 panic disorder 29.8 CRH HTR1A HTR2A MAOA POMC SLC6A4
15 depression 29.7 BDNF CRH CRHR1 HTR1A HTR2A MAOA
16 amenorrhea 29.7 CRH GNRH1 POMC TRH
17 substance dependence 29.7 BDNF MAOA POMC SLC6A4
18 personality disorder 29.7 BDNF HTR1A HTR2A MAOA SLC6A4 TPH1
19 premenstrual tension 29.7 CRH GNRH1 POMC
20 agoraphobia 29.7 HTR1A MAOA SLC6A4
21 irritable bowel syndrome 29.6 CRH CRHR1 SLC6A4 TPH1
22 acth deficiency, isolated 29.5 CRH POMC
23 obsessive-compulsive disorder 29.5 BDNF CRH HTR1A HTR2A MAOA SLC6A4
24 sleep apnea 29.5 HTR2A IL1B INS
25 post-traumatic stress disorder 29.5 BDNF CRH HTR2A IL1B MAOA NR3C1
26 fibromyalgia 29.5 CRH HTR2A NPY SLC6A4
27 migraine with or without aura 1 29.5 HTR1A HTR2A MAOA SLC6A4 TPH1
28 psychotic disorder 29.4 BDNF HTR1A HTR2A SLC6A4 TPH1
29 intermittent explosive disorder 29.4 HTR1A NPY SLC6A4
30 eating disorder 29.3 BDNF CRH NPY POMC SLC6A4
31 conn's syndrome 29.2 CRH NR3C1 POMC
32 substance abuse 29.2 BDNF MAOA NPY SLC6A4
33 autism 29.1 BDNF HTR1A HTR2A SLC6A4
34 bulimia nervosa 29.1 BDNF HTR2A NPY SLC6A4
35 parkinson disease, late-onset 29.0 BDNF HTR1A HTR2A MAOA SLC6A4
36 attention deficit-hyperactivity disorder 29.0 BDNF HTR1A HTR2A MAOA NPY SLC6A4
37 kleptomania 29.0 GATA3 HTR1A MAOA SLC6A4
38 disease of mental health 28.9 BDNF CRH HTR1A HTR2A MAOA POMC
39 asthma 28.8 BDNF GATA3 IL1B NR3C1 POMC
40 borderline personality disorder 28.8 BDNF HTR1A HTR2A MAOA NR3C1 SLC6A4
41 generalized anxiety disorder 28.8 BDNF CRHR1 HTR1A HTR2A MAOA SLC6A4
42 major depressive disorder 28.6 BDNF CRH CRHR1 GATA3 HTR1A HTR2A
43 body mass index quantitative trait locus 11 28.6 CRH INS NPY NR3C1 POMC
44 anorexia nervosa 28.5 BDNF CRH HTR2A NPY POMC SLC6A4
45 chronic fatigue syndrome 28.3 CRH HTR1A HTR2A IL1B IL2 MAOA
46 schizophrenia 28.3 BDNF HTR1A HTR2A MAOA NPY SLC6A4
47 alcohol dependence 28.3 BDNF CRHR1 HTR1A HTR2A MAOA NPY
48 mental depression 27.5 BDNF CRH CRHR1 GATA3 HTR1A HTR2A
49 mood disorder 27.5 BDNF CRH CRHR1 HTR1A HTR2A MAOA
50 anxiety 27.5 BDNF CRH CRHR1 HTR1A HTR2A MAOA

Graphical network of the top 20 diseases related to Endogenous Depression:



Diseases related to Endogenous Depression

Symptoms & Phenotypes for Endogenous Depression

UMLS symptoms related to Endogenous Depression:


depressed - symptom

MGI Mouse Phenotypes related to Endogenous Depression:

47 (show all 14)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.34 BDNF CRH CRHR1 HTR1A HTR2A IL2
2 homeostasis/metabolism MP:0005376 10.34 BDNF CRH CRHR1 GATA3 GNRH1 HTR1A
3 growth/size/body region MP:0005378 10.27 BDNF CRH GATA3 GNRH1 IL1B IL2
4 endocrine/exocrine gland MP:0005379 10.26 BDNF CRH CRHR1 GATA3 GNRH1 HTR2A
5 cardiovascular system MP:0005385 10.25 CRHR1 GATA3 HTR1A IL1B IL2 INS
6 nervous system MP:0003631 10.17 BDNF CRH CRHR1 GATA3 GNRH1 HTR1A
7 digestive/alimentary MP:0005381 10.1 BDNF GATA3 GNRH1 HTR2A IL2 INS
8 integument MP:0010771 10.1 BDNF CRH GATA3 GNRH1 IL1B INS
9 adipose tissue MP:0005375 10.08 CRH GATA3 INS NPY NR3C1 POMC
10 no phenotypic analysis MP:0003012 9.96 BDNF CRH CRHR1 GATA3 HTR1A IL2
11 liver/biliary system MP:0005370 9.91 CRH GNRH1 IL2 INS NPY NR3C1
12 normal MP:0002873 9.81 BDNF CRH CRHR1 GATA3 GNRH1 INS
13 renal/urinary system MP:0005367 9.5 CRH GATA3 GNRH1 INS NPY NR3C1
14 skeleton MP:0005390 9.28 CRH GATA3 GNRH1 HTR2A IL1B INS

Drugs & Therapeutics for Endogenous Depression

Drugs for Endogenous Depression (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 650)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Citalopram Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 59729-33-8 2771
2
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 62-31-7, 51-61-6 681
3
Norepinephrine Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 51-41-2 439260
4
Fluoxetine Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 54910-89-3 3386
5
Angiotensin II Approved, Investigational Phase 4 68521-88-0, 11128-99-7, 4474-91-3 172198 65143
6
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
7
Sertraline Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 79617-96-2 68617
8
Paroxetine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 61869-08-7 43815
9
Fluvoxamine Approved, Investigational Phase 4,Not Applicable 54739-18-3 3404 5324346
10
Trazodone Approved, Investigational Phase 4,Phase 3 19794-93-5 5533
11
Histamine Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1,Not Applicable 51-45-6 774
12
Bupropion Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 34841-39-9, 34911-55-2 444
13
Mirtazapine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 61337-67-5, 85650-52-8 4205
14
Clonazepam Approved, Illicit Phase 4 1622-61-3 2802
15
Reboxetine Approved, Experimental Phase 4,Phase 2,Not Applicable 98769-81-4, 71620-89-8 65856 123628
16
Buspirone Approved, Investigational Phase 4,Phase 2 36505-84-7 2477
17
Eszopiclone Approved, Investigational Phase 4,Phase 3 138729-47-2 969472
18
Etomidate Approved Phase 4,Not Applicable 33125-97-2 36339 667484
19
Ketamine Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 6740-88-1 3821
20
Vortioxetine Approved, Investigational Phase 4,Phase 3,Phase 2,Early Phase 1 508233-74-7 9966051
21
Acetylcholine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 51-84-3 187
22
Parathyroid hormone Approved, Investigational Phase 4,Phase 3 9002-64-6
23
Ethanol Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 64-17-5 702
24
Nortriptyline Approved Phase 4,Phase 1,Phase 2,Not Applicable 72-69-5 4543
25
Trimipramine Approved Phase 4 739-71-9 5584 4055
26
Perphenazine Approved Phase 4,Phase 3,Phase 2,Not Applicable 58-39-9 4748
27
Amitriptyline Approved Phase 4,Phase 3,Phase 2,Not Applicable 50-48-6 2160
28
Ropinirole Approved, Investigational Phase 4,Not Applicable 91374-21-9, 91374-20-8 5095 497540
29
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
30
Remifentanil Approved Phase 4 132875-61-7 60815
31
Levomilnacipran Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 96847-54-0
32
Milnacipran Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 92623-85-3 65833
33
Imipramine Approved Phase 4,Not Applicable 50-49-7 3696
34
Pregabalin Approved, Illicit, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 148553-50-8 5486971
35
Lamotrigine Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 84057-84-1 3878
36
Lithium carbonate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 554-13-2
37
Aripiprazole Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 129722-12-9 60795
38
Risperidone Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1 106266-06-2 5073
39
Moclobemide Approved, Investigational Phase 4,Not Applicable,Early Phase 1 71320-77-9 4235
40
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 94-09-7, 1994-09-7 2337
41
tannic acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 1401-55-4
42
Nicotine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 54-11-5 942 89594
43
Hydrocortisone acetate Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 50-03-3
44
Hydrocortisone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 50-23-7 5754
45
Minocycline Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 10118-90-8 5281021
46
Ondansetron Approved Phase 4,Phase 2,Phase 1 99614-02-5 4595
47
Propofol Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 2078-54-8 4943
48
Acetaminophen Approved Phase 4,Phase 2 103-90-2 1983
49
Methylphenidate Approved, Investigational Phase 4,Phase 3 113-45-1 4158
50
Simvastatin Approved Phase 4,Phase 3,Phase 1 79902-63-9 54454

Interventional clinical trials:

(show top 50) (show all 2638)
# Name Status NCT ID Phase Drugs
1 Escitalopram in the Treatment of Adolescents With Major Depressive Disorder or Anxiety Disorders Unknown status NCT03122158 Phase 4 Escitalopram
2 Inflammatory Markers and Cognitive Function in Major Depression Unknown status NCT01391221 Phase 4 Duloxetine
3 Role of Inflammation Factors and Insulin Resistance in Major Depressive Disorder Unknown status NCT01699490 Phase 4 Fluoxetine + Valsartan;Fluoxetine + Placebo
4 Integral Assessment in Unipolar Depression Unknown status NCT02268487 Phase 4 Sertraline
5 Magnetic Resonance Imaging Study of Cognitive-Behavior Therapy for Major Depressive Disorder Unknown status NCT01460212 Phase 4 SSRI antidepressants
6 Algorithm Guided Treatment Strategies for Major Depressive Disorder Unknown status NCT01764867 Phase 4 Escitalopram;Mirtazapine;Fluoxetine;Citalopram;Escitalopram;Paroxetine;Sertraline;Fluvoxamine;Venlafaxine;Duloxetine;Mirtazapine;Bupropion;Trazodone
7 Beta-arrestins and Response to Venlafaxine in Major Depressive Disorder (MDD) (DEPARRESTCLIN) Unknown status NCT02051413 Phase 4 Venlafaxine extended release
8 Electrophysiologic Parameters and Biomarkers Predicting Treatment Response in Patients With Major Depressive Disorder Unknown status NCT01997580 Phase 4 escitalopram
9 Neurochemical, Metabonomics and Neuroimaging Characterization of TCM Diagnostic Subtypes of Major Depression Disorder Unknown status NCT02346682 Phase 4 venlafaxine
10 Cardiovascular Effects of Agomelatine and Escitalopram in Patients With Major Depressive Disorder (MDD) Unknown status NCT01483053 Phase 4 Agomelatine;Escitalopram
11 Duloxetine for Major Depression in Peri-/Postmenopausal Women Unknown status NCT00889369 Phase 4 Duloxetine
12 Effect of Partial Sleep Deprivation on Cognition and Cytokines in Individuals With Major Depression Unknown status NCT00291239 Phase 4
13 Prediction of Antidepressant Treatment Response Using Machine Learning Classification Analysis Unknown status NCT02330679 Phase 4 Desvenlafaxine;Placebo
14 Effect of Escitalopram vs. Reboxetine on Gastro-intestinal Sensitivity of Patients With Major Depressive Disorder Unknown status NCT00209807 Phase 4 escitalopram;Reboxetine
15 Efficacy Study of Escitalopram for Depression in Patients With Diabetes Unknown status NCT00650897 Phase 4 Escitalopram
16 Escitalopram and Sleep Architecture in Patients With Major Depressive Disorder Unknown status NCT00442481 Phase 4 Escitalopram
17 Randomized,Controlled and Open-label Study of Buspirone add-on Treatment in Patients With Major Depression Disorder Unknown status NCT02273154 Phase 4 Buspirone;Paroxetine
18 Brain Mechanisms and Targeting Insomnia in Major Depression Unknown status NCT00628914 Phase 4 escitalopram and eszopiclone;Escitalopram, eszopiclone, and placebo;Escitalopram
19 Effect of Antidepressants on White Matter Structure Unknown status NCT01492621 Phase 4 Desvenlafaxine
20 Effectiveness of Repetitive Transcranial Magnetic Stimulation in Depressed Patients Unknown status NCT02213016 Phase 4
21 Hyperventilation Combined With Etomidate or Ketamine Anesthesia in ECT Treatment of Major Depression Unknown status NCT02924090 Phase 4 Etomidate;Ketamine
22 Vortioxetine Versus Placebo in Major Depressive Disorder Comorbid With Social Anxiety Disorder Unknown status NCT02294305 Phase 4 Vortioxetine;Placebo
23 Efficacy Study of Botox for Depression Unknown status NCT01556971 Phase 4 Botox;Saline Solution
24 Hippocampal Volume in Young Patients With Major Depression Before and After Combined Antidepressive Therapy Unknown status NCT00150839 Phase 4 Mirtazapine;Venlafaxine
25 Clinical Pharmacogenomics of Antidepressant Response Unknown status NCT00269334 Phase 4 Using Citalopram(drug) or Paroxetine(drug)
26 Antidepressant Maintenance in Traumatic Brain Injury Unknown status NCT00162916 Phase 4 citalopram;Placebo
27 The Effect of Quetiapine XR in Depressive Patients Showing Aberrant N100 Amplitude Slope Unknown status NCT01357967 Phase 4 SSRI monotherapy;Seroquel XR adjunctive
28 Benefits of Switching Antidepressants Following Early Nonresponse Unknown status NCT00519012 Phase 4 Sertraline to Paroxetine;Paroxetine to Sertraline
29 Can Vitamin D3 Supplementation Affect Treatment Outcomes in Patients With Depression Unknown status NCT01390662 Phase 4
30 Fluoxetine and Bupropion to Treat Patients With Depression and Alcoholism Unknown status NCT00449007 Phase 4 fluoxetine;bupropion
31 Pharmacogenomics Studies of Antidepressants Unknown status NCT01204086 Phase 4 Venlafaxine;Fluoxetine
32 Optimizing Antidepressant Treatment by Genotype-dependent Adjustment of Medication According to the ABCB1 Gene Unknown status NCT02237937 Phase 4 Paroxetine;Sertraline;Citalopram;Venlafaxine;Amitriptyline;Escitalopram;Amitriptylinoxide;Nortriptyline;Trimipramine
33 A Placebo Controlled Trial of the Dopamine D-2 Receptor Agonist Ropinirole in Treatment of 60 Patients With Refractory Bipolar Depression. Unknown status NCT00335205 Phase 4 ropinirole
34 Effect of the Addition of Ketamine to Sevoflurane Anesthesia in Electroconvulsive Therapy Unknown status NCT02267980 Phase 4 Sevoflurane;Ketamine;Saline
35 The Effects of Remifentanil on Attenuating the Hemodynamic Responses After Electroconvulsive Therapy Unknown status NCT02271555 Phase 4 Sevoflurane;Remifentanil;Saline
36 Study to Evaluate the Efficacy of Milnacipran in the Treatment of Pain Due to Osteoarthritis Unknown status NCT01329406 Phase 4 Milnacipran;Placebo
37 Depression Care Management for Depressed Elders in China Primary Care Unknown status NCT01287494 Phase 4 Sertraline
38 Myoinositol for the Treatment of Ovarian and Psychiatric Disorder in Polycystic Ovary Syndrome (PCOS) Patients Unknown status NCT01246310 Phase 4
39 SmartTouch Catheter for Left Anterior Line - SmarT Line Study Unknown status NCT02217657 Phase 4
40 Reboxetine Treatment in Depressed Children and Adolescents an 8-Week, Open Study Unknown status NCT00426946 Phase 4 Reboxetine
41 Imipramine and Pregabalin Combination in Painful Polyneuropathy Unknown status NCT01047488 Phase 4 Imipramine;Pregabalin;Imipramine, pregabalin;Placebo
42 Natural Supplements for Unipolar Depression Completed NCT00226356 Phase 4 Supplements of L-methionine, betaine and folate
43 Effects of Treatment on Decision-making in Major Depression Completed NCT01916824 Phase 4 Any FDA Approved Antidepressant
44 Open Trial of Duloxetine in Outpatients With Irritable Bowel Syndrome Symptoms and Co-Morbid Major Depression Completed NCT01754493 Phase 4 Duloxetine
45 Safety and Efficacy of Vilazodone in Major Depressive Disorder Completed NCT01473381 Phase 4 Vilazodone;Placebo to citalopram;Placebo to vilazodone;Citalopram
46 Safety, Efficacy, and Tolerability of Vilazodone in Major Depressive Disorder Completed NCT01473394 Phase 4 Dose-matched placebo;Vilazodone
47 Wellbutrin XL, Major Depressive Disorder and Breast Cancer Completed NCT00234195 Phase 4 bupropion extended release (Wellbutrin XL)
48 Research Study for Major Depressive Disorder: Investigation of Glutamate Medications Completed NCT00419003 Phase 4 Lamotrigine;Ketamine;Riluzole
49 Safety and Efficacy of Vilazodone in Major Depressive Disorder Completed NCT01573598 Phase 4 Placebo;Vilazodone;Vilazodone
50 Efficacy and Tolerability of Escitalopram and Duloxetine in Outpatients With Major Depressive Disorder Completed NCT01148472 Phase 4 Escitalopram;Duloxetine

Search NIH Clinical Center for Endogenous Depression

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cochrane evidence based reviews: depressive disorder

Genetic Tests for Endogenous Depression

Anatomical Context for Endogenous Depression

MalaCards organs/tissues related to Endogenous Depression:

42
Brain, Testes, Heart, Cortex, Pituitary, Prefrontal Cortex, Breast

Publications for Endogenous Depression

Articles related to Endogenous Depression:

(show top 50) (show all 1028)
# Title Authors Year
1
Correlation of proinflammatory cytokines levels and reduced gray matter volumes between patients with bipolar disorder and unipolar depression. ( 30359810 )
2019
2
A functional variant in the serotonin receptor 7 gene (HTR7), rs7905446, is associated with good response to SSRIs in bipolar and unipolar depression. ( 30874608 )
2019
3
Lithium continuation therapy following ketamine in patients with treatment resistant unipolar depression: a randomized controlled trial. ( 30858518 )
2019
4
Reply to: Two Methodologies in "Amygdala Activation and Connectivity to Emotional Processing Distinguishes Asymptomatic Patients With Bipolar Disorders and Unipolar Depression" That Can Produce False-Positive Results and Some Statistical Recommendations. ( 30733112 )
2019
5
Two Methodologies in "Amygdala Activation and Connectivity to Emotional Processing Distinguishes Asymptomatic Patients With Bipolar Disorders and Unipolar Depression" That Can Produce False-Positive Results and Some Statistical Recommendations. ( 30733113 )
2019
6
A systematic review of measures of medication adherence in consumers with unipolar depression. ( 29526664 )
2019
7
Differentiating between bipolar and unipolar depression in functional and structural MRI studies. ( 29601896 )
2019
8
Treatment effectiveness and tolerability outcomes that are most important to individuals with bipolar and unipolar depression. ( 30241026 )
2019
9
Differentiation of Transformed Bipolar Disorder From Unipolar Depression by Resting-State Functional Connectivity Within Reward Circuit. ( 30622492 )
2018
10
Childhood maltreatment and adult medical morbidity in mood disorders: comparison of unipolar depression with bipolar disorder. ( 30232950 )
2018
11
Red Blood Cells Parameters in Patients with Acute Schizophrenia, Unipolar Depression and Bipolar Disorder. ( 30267525 )
2018
12
Artistic creativity and risk for schizophrenia, bipolar disorder and unipolar depression: a Swedish population-based case-control study and sib-pair analysis. ( 29697041 )
2018
13
Patterns and predictors of conversion to bipolar disorder in 91 587 individuals diagnosed with unipolar depression. ( 29498031 )
2018
14
Substance Dependence Among Bipolar, Unipolar Depression and Psychotic Homeless: A Canadian National Study. ( 30618874 )
2018
15
Factors That Impact Treatment Decisions: Results From an Online Survey of Individuals With Bipolar and Unipolar Depression. ( 30444959 )
2018
16
Frequency of use and perceived helpfulness of wellness strategies for bipolar and unipolar depression. ( 30372507 )
2018
17
Amygdala Activation and Connectivity to Emotional Processing Distinguishes Asymptomatic Patients With Bipolar Disorders and Unipolar Depression. ( 30343134 )
2018
18
Consumer-related factors influencing antidepressant adherence in unipolar depression: a qualitative study. ( 30288027 )
2018
19
Language bias and comprehensive meta-analysis of folate for unipolar depression. ( 30293526 )
2018
20
Electroconvulsive therapy in unipolar depression treatment guidelines. ( 30295322 )
2018
21
Motor activity patterns in acute schizophrenia and other psychotic disorders can be differentiated from bipolar mania and unipolar depression. ( 30312969 )
2018
22
A Randomized Controlled Pilot Study on Mindfulness-Based Cognitive Therapy for Unipolar Depression in Patients With Chronic Pain. ( 28252881 )
2018
23
Differentiating bipolar disorders from unipolar depression by applying the Brief Assessment of Cognition in Affective Disorders. ( 28826415 )
2018
24
Antidepressant combination versus antidepressants plus second-generation antipsychotic augmentation in treatment-resistant unipolar depression. ( 28906325 )
2018
25
Decreased Pretreatment Amygdalae Serotonin Transporter Binding in Unipolar Depression Remitters: A Prospective PET Study. ( 28935838 )
2018
26
Body composition does not affect serum levels of cathelicidin LL-37 in elderly women with unipolar depression. ( 28959904 )
2018
27
Low left amygdala volume is associated with a longer duration of unipolar depression. ( 29159580 )
2018
28
Attentional biases in patients suffering from unipolar depression: results of a dot probe task investigation. ( 29331850 )
2018
29
Alterations in peripheral fatty acid composition in bipolar and unipolar depression. ( 29336895 )
2018
30
Hippocampal shape alterations in healthy young women with familial risk for unipolar depression. ( 29367060 )
2018
31
Cognitive Impairment In Treatment-Naïve Bipolar II and Unipolar Depression. ( 29382902 )
2018
32
Shared and distinct regional homogeneity changes in bipolar and unipolar depression. ( 29466722 )
2018
33
Psychopathological and sociodemographic features in treatment-resistant unipolar depression versus bipolar depression: a comparative study. ( 29548306 )
2018
34
Comparison of guidelines for the treatment of unipolar depression: a focus on pharmacotherapy and neurostimulation. ( 29577229 )
2018
35
Functional Connectivity Between Anterior Insula and Key Nodes of Frontoparietal Executive Control and Salience Networks Distinguish Bipolar Depression From Unipolar Depression and Healthy Control Subjects. ( 29580768 )
2018
36
Neural correlates of processing emotional prosody in unipolar depression. ( 29682814 )
2018
37
Inpatient Volume and Quality of Mental Health Care Among Patients With Unipolar Depression. ( 29695225 )
2018
38
A quantitative review on outcome-to-antidepressants in melancholic unipolar depression. ( 29702301 )
2018
39
Mortality in unipolar depression preceding and following chronic somatic diseases. ( 29761489 )
2018
40
A Comparative Study of Different EEG Reference Choices for Diagnosing Unipolar Depression. ( 29860588 )
2018
41
The association of duration and severity of disease with executive function: Differences between drug-naïve patients with bipolar and unipolar depression. ( 29909305 )
2018
42
Mortality in treatment-resistant unipolar depression: A register-based cohort study in Sweden. ( 29966932 )
2018
43
Effects of different endurance exercise modalities on retinal vessel diameters in unipolar depression. ( 30048648 )
2018
44
Study supports augmentation with a non-antidepressant agent over combining or switching antidepressants in unipolar depression. ( 30054446 )
2018
45
Effects of Magnesium Supplementation on Unipolar Depression: A Placebo-Controlled Study and Review of the Importance of Dosing and Magnesium Status in the Therapeutic Response. ( 30081500 )
2018
46
Differential response to lithium between melancholic and non-melancholic unipolar depression. ( 30149276 )
2018
47
Brief Social Isolation in the Adolescent Wistar-Kyoto Rat Model of Endogenous Depression Alters Corticosterone and Regional Monoamine Concentrations. ( 28233145 )
2017
48
Immediate and delayed anxiety- and depression-like profiles in the adolescent Wistar-Kyoto rat model of endogenous depression following postweaning social isolation. ( 28017851 )
2017
49
The prevalence and outcomes of exposure to potentially traumatic stressful life events compared across patients with bipolar disorder and unipolar depression. ( 28667927 )
2017
50
Topologically convergent and divergent functional connectivity patterns in unmedicated unipolar depression and bipolar disorder. ( 28675389 )
2017

Variations for Endogenous Depression

Copy number variations for Endogenous Depression from CNVD:

7 (show all 23)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 30014 1 239103312 239231293 Duplication RGS7 Depressive disorder
2 46482 10 81631178 81930681 Duplication ANXA11 Depressive disorder
3 46483 10 81631178 81930681 Duplication C10orf57 Depressive disorder
4 46484 10 81631178 81930681 Duplication PLAC9 Depressive disorder
5 46485 10 81631178 81930681 Duplication SFTPD Depressive disorder
6 49583 11 108105203 108301884 Duplication DDX10 Depressive disorder
7 96990 15 97399748 97770838 Duplication LRRC28 Depressive disorder
8 96991 15 97399748 97770838 Duplication TTC23 Depressive disorder
9 188464 4 65074807 68777792 Duplication CENPC1 Depressive disorder
10 188465 4 65074807 68777792 Duplication EPHA5 Depressive disorder
11 188466 4 65074807 68777792 Duplication GNRHR Depressive disorder
12 188467 4 65074807 68777792 Duplication STAP1 Depressive disorder
13 188468 11 117276569 117305325 Duplication TMPRSS11 Depressive disorder
14 188469 4 65074807 68777792 Duplication UBA6 Depressive disorder
15 192627 5 115261015 115369537 Duplication AP3S1 Depressive disorder
16 196524 5 168423758 169070607 Duplication CCDC99 Depressive disorder
17 196525 5 168423758 169070607 Duplication DOCK2 Depressive disorder
18 196526 5 168423758 169070607 Duplication SLIT3 Depressive disorder
19 198486 5 25121416 25298271 Duplication CDH10 Depressive disorder
20 223205 7 17201925 17473214 Duplication AHR Depressive disorder
21 223742 7 24922773 25040936 Duplication OSBPL3 Depressive disorder
22 228816 7 8241584 8363438 Duplication ICA1 Depressive disorder
23 237111 8 21188347 21318056 Duplication GFRA2 Depressive disorder

Expression for Endogenous Depression

Search GEO for disease gene expression data for Endogenous Depression.

Pathways for Endogenous Depression

Pathways related to Endogenous Depression according to GeneCards Suite gene sharing:

(show all 20)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.96 CRH CRHR1 GNRH1 HTR1A HTR2A IL2
2
Show member pathways
13.34 CRH CRHR1 GNRH1 HTR1A HTR2A NPY
3
Show member pathways
12.91 BDNF CRH CRHR1 HTR2A POMC
4 12.37 HTR1A NPY POMC TPH1
5
Show member pathways
12.06 BDNF GNRH1 IL1B IL2
6
Show member pathways
11.89 BDNF GNRH1 IL1B IL2
7 11.88 GATA3 INS NR3C1
8
Show member pathways
11.86 GATA3 IL1B IL2
9 11.81 BDNF IL1B IL2
10 11.79 GATA3 IL1B MAOA POMC
11 11.64 CRH CRHR1 IL2 POMC
12 11.61 HTR1A HTR2A MAOA SLC6A4 TPH1
13 11.59 GATA3 IL1B IL2
14 11.54 GATA3 IL2 NR3C1 POMC
15 11.52 BDNF IL1B IL2
16 11.49 BDNF GATA3 HTR1A HTR2A IL1B MAOA
17
Show member pathways
11.45 IL1B IL2 NR3C1
18
Show member pathways
11.27 IL1B MAOA SLC6A4
19 10.8 HTR1A HTR2A MAOA SLC6A4 TPH1
20 10.28 CRH CRHR1 POMC

GO Terms for Endogenous Depression

Cellular components related to Endogenous Depression according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.56 BDNF CRH GNRH1 IL1B IL2 INS
2 secretory granule GO:0030141 9.33 IL1B POMC TRH
3 extracellular region GO:0005576 9.28 BDNF CRH GNRH1 IL1B IL2 INS

Biological processes related to Endogenous Depression according to GeneCards Suite gene sharing:

(show all 28)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 9.97 CRH HTR1A HTR2A IL1B IL2 INS
2 positive regulation of gene expression GO:0010628 9.92 CRH GATA3 IL1B INS SLC6A4
3 chemical synaptic transmission GO:0007268 9.88 CRH HTR1A HTR2A NPY
4 cytokine-mediated signaling pathway GO:0019221 9.88 GATA3 IL1B IL2 MAOA POMC
5 G protein-coupled receptor signaling pathway GO:0007186 9.85 CRH CRHR1 GNRH1 HTR1A HTR2A IL2
6 response to drug GO:0042493 9.81 CRH GATA3 HTR2A SLC6A4
7 female pregnancy GO:0007565 9.77 CRH CRHR1 GNRH1
8 G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger GO:0007187 9.73 HTR1A HTR2A NPY
9 cell-cell signaling GO:0007267 9.73 GNRH1 IL1B IL2 INS POMC TRH
10 response to organic cyclic compound GO:0014070 9.64 GNRH1 TRH
11 positive regulation of glycolytic process GO:0045821 9.63 HTR2A INS
12 positive regulation of kinase activity GO:0033674 9.63 HTR2A IL2
13 positive regulation of T cell differentiation GO:0045582 9.62 GATA3 IL2
14 response to corticosterone GO:0051412 9.62 CRH TRH
15 negative regulation of lipid catabolic process GO:0050995 9.61 IL1B INS
16 vasoconstriction GO:0042310 9.61 HTR1A SLC6A4
17 parturition GO:0007567 9.59 CRH CRHR1
18 behavior GO:0007610 9.58 HTR1A HTR2A
19 serotonin receptor signaling pathway GO:0007210 9.57 HTR1A HTR2A
20 regulation of signaling receptor activity GO:0010469 9.56 BDNF GNRH1 IL1B IL2 INS NPY
21 negative regulation of feeding behavior GO:2000252 9.55 INS TRH
22 memory GO:0007613 9.54 BDNF HTR2A SLC6A4
23 regulation of corticosterone secretion GO:2000852 9.46 CRHR1 POMC
24 regulation of serotonin secretion GO:0014062 9.43 CRH HTR1A
25 response to immobilization stress GO:0035902 9.4 CRH TPH1
26 negative regulation of glutamate secretion GO:0014050 9.24 TRH
27 response to ethanol GO:0045471 9.02 CRH GATA3 GNRH1 IL2 TRH
28 signal transduction GO:0007165 10.02 CRH CRHR1 GATA3 GNRH1 HTR1A HTR2A

Molecular functions related to Endogenous Depression according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 interleukin-2 receptor binding GO:0005134 9.16 GATA3 IL2
2 serotonin binding GO:0051378 9.13 HTR1A HTR2A SLC6A4
3 hormone activity GO:0005179 9.1 CRH GNRH1 INS NPY POMC TRH

Sources for Endogenous Depression

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71